Status:
COMPLETED
SLV308 for Treatment of Patients With Early Parkinson's Disease
Lead Sponsor:
Solvay Pharmaceuticals
Conditions:
Early Stage Parkinson's Disease
Eligibility:
All Genders
30+ years
Phase:
PHASE3
Brief Summary
This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety exten...
Eligibility Criteria
Inclusion
- Diagnosis of idiopathic Parkinson's Disease,
- Early stage of disease, Modified Hoehn \& Yahr up to stage III,
- UPDRS motor score (part III) 10 at baseline.
Exclusion
- Diagnosis is unclear or a suspicion of other parkinsonian syndromes,
- Patients who have undergone surgery for the treatment of PD,
- Presence of dyskinesias,
- Motor fluctuations or loss of postural reflexes,
- Clinically significant abnormalities,
- Patients treated with L-dopa or dopamine agonists currently or in the past (for more than 3 months in total),
- Antipsychotic.
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
468 Patients enrolled
Trial Details
Trial ID
NCT00269516
Start Date
June 1 2006
End Date
December 1 2007
Last Update
August 29 2008
Active Locations (128)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 284
Huntsville, Alabama, United States
2
Site 274
Little Rock, Arkansas, United States
3
Site 283
Fountain Valley, California, United States
4
Site 277
La Jolla, California, United States